AbbVie Inc.’s Humira lost 2% of market share to biosimilars in the US in 2023, the first year the blockbuster drug faced direct copycat competition.
Key Takeaways
- Humira’s continued strong formulary position in its second year facing biosimilar competition is discouraging health policy experts and generic executives alike about the prospects for future biosimilar launches.
Charts at the bottom of the story detail biosimilar formulary position by product and category.
2024 isn’t shaping up to be a whole lot worse for the biologic – two of the three major pharmacy...






